These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28980281)

  • 1. Evaluating the effects of cardiac resynchronization therapy on pathophysiological pathways of heart failure using surrogate biomarkers.
    Sunman H; Özkan A; Yorgun H; Canpolat U; Karabulut E; Bayrak T; Kaya EB; Tokgözoğlu L; Özer N; Özkara A; Aytemir K; Oto A
    Cardiol J; 2018; 25(1):42-51. PubMed ID: 28980281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High sensitivity C-reactive protein predicts nonresponders and cardiac deaths in severe heart failure patients after CRT implantation.
    Kamioka M; Suzuki H; Yamada S; Kamiyama Y; Saitoh S; Takeishi Y
    Int Heart J; 2012; 53(5):306-12. PubMed ID: 23038092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cardiac resynchronization therapy on inflammatory biomarkers and cardiac remodeling: The paradox of functional and echocardiographic response.
    Almeida-Morais L; Abreu A; Oliveira M; Silva Cunha P; Rodrigues I; Portugal G; Rio P; Soares R; Mota Carmo M; Cruz Ferreira R
    Rev Port Cardiol (Engl Ed); 2018 Feb; 37(2):105-113. PubMed ID: 29503051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT.
    Medina A; Moss AJ; McNitt S; Zareba W; Wang PJ; Goldenberg I
    Heart Rhythm; 2016 Apr; 13(4):852-9. PubMed ID: 26724489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study.
    Truong QA; Januzzi JL; Szymonifka J; Thai WE; Wai B; Lavender Z; Sharma U; Sandoval RM; Grunau ZS; Basnet S; Babatunde A; Ajijola OA; Min JK; Singh JP
    Heart Rhythm; 2014 Dec; 11(12):2167-75. PubMed ID: 25014756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure.
    Dong YX; Burnett JC; Chen HH; Sandberg S; Yang YZ; Zhang Y; Chen PS; Cha YM
    J Interv Card Electrophysiol; 2011 Apr; 30(3):241-9. PubMed ID: 21336616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
    Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
    Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Usefulness of N-terminal Prohormone of Brain Natriuretic Peptide and High Sensitivity Troponin T in Patients with Heart Failure Undergoing Cardiac Resynchronization Therapy.
    Debska-Kozlowska A; Ksiazczyk M; Warchol I; Lubinski A
    Curr Pharm Des; 2019; 25(14):1671-1678. PubMed ID: 31223080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study.
    Beaudoin J; Singh JP; Szymonifka J; Zhou Q; Levine RA; Januzzi JL; Truong QA
    Can J Cardiol; 2016 Dec; 32(12):1478-1484. PubMed ID: 27527259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory activation following interruption of long-term cardiac resynchronization therapy.
    Rubaj A; Ruciński P; Oleszczak K; Trojnar MK; Wójcik M; Wysokiński A; Kutarski A
    Heart Vessels; 2013 Sep; 28(5):583-8. PubMed ID: 23242167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects.
    Stanciu AE; Vatasescu RG; Stanciu MM; Iorgulescu C; Vasile AI; Dorobantu M
    Clin Biochem; 2013 Feb; 46(3):230-4. PubMed ID: 23159290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy.
    Lellouche N; De Diego C; Cesario DA; Vaseghi M; Horowitz BN; Mahajan A; Wiener I; Boyle NG; Fonarow GC; Shivkumar K
    Am J Cardiol; 2007 Jan; 99(2):242-6. PubMed ID: 17223426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients.
    Kosztin A; Kutyifa V; Nagy VK; Geller L; Zima E; Molnar L; Szilagyi S; Ozcan EE; Szeplaki G; Merkely B
    Europace; 2016 Apr; 18(4):550-9. PubMed ID: 26116830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin is associated with reverse remodeling after cardiac resynchronization therapy in patients with heart failure and ventricular dyssynchrony.
    Dominguez-Rodriguez A; Abreu-Gonzalez P; Piccolo R; Galasso G; Reiter RJ
    Int J Cardiol; 2016 Oct; 221():359-63. PubMed ID: 27404706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Left Ventricular vs Biventricular Pacing on Reverse Remodelling: Insights From the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) Trial.
    Skaf S; Thibault B; Khairy P; O'Meara E; Fortier A; Vakulenko HV; Pitre C; White M; Ducharme A;
    Can J Cardiol; 2017 Oct; 33(10):1274-1282. PubMed ID: 28941607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echocardiography-based qualification and response assessment to cardiac resynchronisation therapy in patients with chronic heart failure. The matrix metalloproteinase-9 substudy.
    Szulik M; Stabryła-Deska J; Boidol J; Lenarczyk R; Kalarus Z; Kukulski T
    Kardiol Pol; 2011; 69(10):1043-51. PubMed ID: 22006606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study.
    Gold MR; Daubert C; Abraham WT; Ghio S; St John Sutton M; Hudnall JH; Cerkvenik J; Linde C
    Heart Rhythm; 2015 Mar; 12(3):524-530. PubMed ID: 25460860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of left ventricular reverse remodeling and brain natriuretic peptide level at one year after cardiac resynchronization therapy predicts long-term clinical outcome.
    Roubicek T; Stros J; Kucera P; Nedbal P; Cerny J; Polasek R; Wichterle D
    PLoS One; 2019; 14(7):e0219966. PubMed ID: 31314790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response.
    Sultan A; Wörmann J; Lüker J; V D Bruck J-; Plenge T; Rudolph V; Klinke A; Heijman J; Mollenhauer M; Ravekes T; Baldus S; Steven D
    Clin Res Cardiol; 2021 Aug; 110(8):1173-1180. PubMed ID: 32564144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.